List of Prevduo drug patents

Prevduo is owned by Slayback Pharma Llc.

Prevduo contains Glycopyrrolate; Neostigmine Methylsulfate.

Prevduo has a total of 2 drug patents out of which 0 drug patents have expired.

Prevduo was authorised for market use on 23 February, 2023.

Prevduo is available in solution;intravenous dosage forms.

The generics of Prevduo are possible to be released after 25 October, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456354 SLAYBACK PHARMA LLC Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(15 years from now)

US11110054 SLAYBACK PHARMA LLC Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(15 years from now)

Do you want to check out PREVDUO patents from before 2022?

Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient

Market Authorisation Date: 23 February, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in